

# Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice

NCT05928286

---

|            |   |
|------------|---|
| Status     | RECRUITING  |
| Sponsor    | POLYSAN Scientific & Technological Pharmaceutical Company |
| Enrollment | 286 participants  |

## Key Eligibility Criteria

---

### Inclusion (6)

- Signed informed consent form.
  - Age from 18 to 70 years
  - Diagnosis: Gallstone disease. Cholelithiasis, choledocholithiasis. Obstructive jaundice.
  - Total bilirubin level in the blood in the range from 102.5 to 246 µmol/l.
  - Jaundice duration according to the patient is not more than 7 days.
- ... and 1 more (see full listing online)

### Exclusion (14)

- Presence of other pathology causing jaundice syndrome (tumors, constrictions, etc.).
  - Acute cholangitis. Acute cholecystitis. Acute pancreatitis.
  - History of chronic viral hepatitis, hepatic cirrhosis.
  - Other surgical pathology aggravating the condition and/or requiring treatment.
  - Use in the treatment of drugs containing ademethionine.
- ... and 9 more (see full listing online)

## Locations (9 total)

---

Krai Clinical Hospital, Barnaul, Russia  
Hospital for War Veterans, Kazan', Russia  
City Clinical Hospital No. 7, Nizhny Novgorod, Russia  
... and 6 more locations